Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-CTLs for Refractory EBV Infection
NCT03266653Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Epstein-Barr virus infection, sponsored by New York Medical College. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks and Incidence of Response to Treatment at 12 weeks. Started Jul 2020; status: recruiting.
02
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT03266653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266653.